Literature DB >> 20926135

Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: Standard Care Versus COrticosteroid for REtinal Vein Occlusion Study report 10.

Ingrid U Scott1, Paul C VanVeldhuisen, Neal L Oden, Michael S Ip, Barbara A Blodi, Mary Elizabeth Hartnett, Geoff Cohen.   

Abstract

OBJECTIVE: To investigate baseline factors associated with visual acuity and central retinal thickness outcomes in patients with macular edema secondary to retinal vein occlusion in the Standard Care versus COrticosteroid for REtinal Vein Occlusion (SCORE) Study.
DESIGN: Two multicenter, randomized clinical trials: one evaluating participants with central retinal vein occlusion (CRVO) and one evaluating participants with branch retinal vein occlusion (BRVO). PARTICIPANTS: Participants with follow-up data of 1 year or more, including 238 with CRVO and 367 with BRVO.
METHODS: Visual acuity was measured by the electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) method, and central retinal thickness was measured by optical coherence tomography (OCT). Regression analysis related these outcomes to 20 baseline measures. Multiple P values were adjusted to control the false discovery rate. MAIN OUTCOME MEASURES: Outcome measures of visual acuity letter score included absolute change from baseline, a gain of ≥ 15 from baseline, and a loss of ≥ 15 from baseline. Outcome measures of center point thickness included absolute change from baseline, a measurement of ≤ 250 μm, and a measurement of ≥ 500 μm. Outcomes were assessed at 1 and 2 years.
RESULTS: For CRVO and BRVO, younger age was associated with improved visual acuity and central retinal thickness outcomes. For CRVO, triamcinolone treatment and less severe anatomic abnormalities of the retina (center point thickness and areas of retinal hemorrhage, thickening, and fluorescein leakage) were predictive of better visual acuity outcomes. For BRVO, no history of coronary artery disease was predictive of improved visual acuity outcomes. For center point thickness outcomes, shorter duration of macular edema was associated with improvement in both disease entities. For CRVO, higher baseline visual acuity letter score was predictive of favorable OCT outcomes. For BRVO, lower baseline visual acuity letter score, presence of dense macular hemorrhage, and no prior grid photocoagulation were predictive of favorable OCT outcomes.
CONCLUSIONS: Several factors were predictive of better visual acuity outcomes and more favorable OCT outcomes, including younger age and shorter duration of macular edema, respectively. These factors may assist clinicians in predicting disease course for patients with CRVO and BRVO.
Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20926135      PMCID: PMC3020981          DOI: 10.1016/j.ophtha.2010.06.034

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  21 in total

1.  Controlling the false discovery rate in behavior genetics research.

Authors:  Y Benjamini; D Drai; G Elmer; N Kafkafi; I Golani
Journal:  Behav Brain Res       Date:  2001-11-01       Impact factor: 3.332

2.  The risk for systemic vascular diseases and mortality in patients with central retinal vein occlusion.

Authors:  M J Elman; A K Bhatt; P M Quinlan; C Enger
Journal:  Ophthalmology       Date:  1990-11       Impact factor: 12.079

3.  Risk factors for retinal vein occlusions. A case-control study.

Authors:  E Z Rath; R N Frank; D H Shin; C Kim
Journal:  Ophthalmology       Date:  1992-04       Impact factor: 12.079

4.  Systemic factors contributory to retinal vein occlusion.

Authors:  M A McGrath; F Wechsler; A B Hunyor; R Penny
Journal:  Arch Intern Med       Date:  1978-02

5.  Risk factors of branch retinal vein occlusion.

Authors:  R L Johnston; A J Brucker; W Steinmann; M E Hoffman; J H Holmes
Journal:  Arch Ophthalmol       Date:  1985-12

6.  Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group.

Authors: 
Journal:  Am J Ophthalmol       Date:  1984-09-15       Impact factor: 5.258

7.  Risk factors associated with branch vs. central retinal vein occlusion.

Authors:  A P Appiah; C L Trempe
Journal:  Ann Ophthalmol       Date:  1989-04

8.  Risk factors for branch retinal vein occlusion. The Eye Disease Case-control Study Group.

Authors: 
Journal:  Am J Ophthalmol       Date:  1993-09-15       Impact factor: 5.258

9.  Factors associated with retinal-vein occlusion in Hispanics.

Authors:  A P Appiah; K C Greenidge
Journal:  Ann Ophthalmol       Date:  1987-08

10.  A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol.

Authors:  Roy W Beck; Pamela S Moke; Andrew H Turpin; Frederick L Ferris; John Paul SanGiovanni; Chris A Johnson; Eileen E Birch; Danielle L Chandler; Terry A Cox; R Clifford Blair; Raymond T Kraker
Journal:  Am J Ophthalmol       Date:  2003-02       Impact factor: 5.258

View more
  29 in total

Review 1.  A comprehensive review of diagnostic imaging technologies to evaluate the retina and the optic disk.

Authors:  Asima Bajwa; Rabia Aman; Ashvini K Reddy
Journal:  Int Ophthalmol       Date:  2015-06-05       Impact factor: 2.031

2.  Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis).

Authors:  Clement K Chan; Atul Jain; Srinivas Sadda; Neeta Varshney
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

3.  Anatomical and functional recurrence after dexamethasone intravitreal implants: a 6-month prospective study.

Authors:  V Fortoul; P Denis; L Kodjikian
Journal:  Eye (Lond)       Date:  2015-03-20       Impact factor: 3.775

4.  Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.

Authors:  Ingrid U Scott; Paul C VanVeldhuisen; Michael S Ip; Barbara A Blodi; Neal L Oden; Jacqueline King; Andrew N Antoszyk; Mark A Peters; Michael Tolentino
Journal:  JAMA Ophthalmol       Date:  2017-06-01       Impact factor: 7.389

5.  Visual function after pars plana vitrectomy in macular edema with branch retinal vein occlusion.

Authors:  Hidetaka Noma; Katsunori Shimada; Tatsuya Mimura
Journal:  Int Ophthalmol       Date:  2012-11-19       Impact factor: 2.031

6.  Characteristics of retinal vein occlusion with final vision better than 78 letters after sequential therapy with ranibizumab and triamcinolone acetate.

Authors:  Yao-Wu Qin; Jia Yu; Quan Zhang
Journal:  Int J Ophthalmol       Date:  2017-02-18       Impact factor: 1.779

7.  Potential anti-vascular endothelial growth factor therapies for central retinal vein occlusion.

Authors:  Marta S Figueroa; Inés Contreras
Journal:  Drugs       Date:  2012-11-12       Impact factor: 9.546

8.  Predictors of short-term outcomes related to central subfield foveal thickness after intravitreal bevacizumab for macular edema due to central retinal vein occlusion.

Authors:  Mei-Zi Wang; Kang Feng; Yao Lu; Fang Qian; Xin-Rong Lu; Si-Wen Zang; Lin Zhao
Journal:  Int J Ophthalmol       Date:  2016-01-18       Impact factor: 1.779

9.  Branch retinal vein occlusion-associated subretinal hemorrhage.

Authors:  Yuki Muraoka; Akitaka Tsujikawa; Tomoaki Murakami; Ken Ogino; Kazuaki Miyamoto; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2013-03-19       Impact factor: 2.447

10.  Improved visual outcome with early treatment in macular edema secondary to retinal vein occlusions: 6-month results of a Korean RVO study.

Authors:  Young Hee Yoon; Ha Kyoung Kim; Hee Seong Yoon; Se Woong Kang; June-Gone Kim; Kyu Hyung Park; Young Joon Jo; Joo Yong Lee; Dong Hoon Lee
Journal:  Jpn J Ophthalmol       Date:  2014-01-31       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.